Dr. Kevin Slawin, MD, Founder, Chairman and CEO of Deliver Therapeutics, Inc., presented the company at this year’s Alexandria Seed Capital Platform’s Seed Catalyst Partnership Meeting held at The Alexandria at Torrey Pines on April 4, 2024, in San Diego, CA. Deliver Therapeutics was one of only three companies selected to present during the Seed Catalyst portion of the meeting. The one-hour workshop included a 20-minute pitch, live Q&A, and open discussion time with the Advisory Board.
Alexandria Venture Investments, the strategic venture capital arm of Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations, launched the Alexandria Seed Capital Platform, a novel and innovative seed-stage life science funding, in 2018. The Alexandria Seed Capital Platform is led by Alexandria Venture Investments and supported by a preeminent Advisory Board of seasoned biopharma and venture capital executives from Accelerator Life Science Partners, ARCH Venture Partners, Eli Lilly and Company, Pfizer and Roche, in evaluating the most promising seed-stage life science startups.
Alexandria Venture Investments vets seed-stage companies of interest through the Seed Capital Platform and guides milestone-driven investments based on the quality and differentiation of a company’s technology, foundational IP, business strategy, financing plan and management team. Leveraging its deep experience in building and nurturing life science companies, Alexandria and the Advisory Board also serves as mentors for the entrepreneurs who receive funding through the platform. This high level of engagement is designed to enhance the trajectory of recipient seed-stage companies and lay a foundation for future investment and collaboration.
